EAM Investors LLC purchased a new stake in shares of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 214,898 shares of the biopharmaceutical company’s stock, valued at approximately $1,526,000. EAM Investors LLC owned about 0.18% of Keryx Biopharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in KERX. Fox Run Management L.L.C. purchased a new stake in shares of Keryx Biopharmaceuticals during the third quarter valued at about $101,000. Principal Financial Group Inc. lifted its position in shares of Keryx Biopharmaceuticals by 4.2% during the second quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 590 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its position in shares of Keryx Biopharmaceuticals by 51.8% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 16,495 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 5,628 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Keryx Biopharmaceuticals by 1.2% during the first quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 300 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Keryx Biopharmaceuticals during the second quarter valued at about $183,000. 65.44% of the stock is owned by institutional investors and hedge funds.

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) opened at $4.83 on Friday. Keryx Biopharmaceuticals, Inc. has a fifty-two week low of $4.47 and a fifty-two week high of $8.38. The company has a debt-to-equity ratio of 13.95, a quick ratio of 3.76 and a current ratio of 4.46.

Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.03). Keryx Biopharmaceuticals had a negative net margin of 323.92% and a negative return on equity of 10,954.62%. The company had revenue of $15.00 million for the quarter, compared to analyst estimates of $18.88 million. During the same quarter last year, the company earned ($0.39) EPS. The business’s revenue was up 138.1% compared to the same quarter last year. analysts forecast that Keryx Biopharmaceuticals, Inc. will post -1.36 earnings per share for the current year.

Several research firms have commented on KERX. BidaskClub raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, August 16th. ValuEngine lowered shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, September 21st. Zacks Investment Research lowered shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, September 14th. Finally, Stifel Nicolaus cut their price objective on shares of Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating on the stock in a report on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $7.35.

ILLEGAL ACTIVITY WARNING: “EAM Investors LLC Takes Position in Keryx Biopharmaceuticals, Inc. (KERX)” was originally published by Daily Political and is the property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.dailypolitical.com/2017/11/25/eam-investors-llc-takes-position-in-keryx-biopharmaceuticals-inc-kerx.html.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Want to see what other hedge funds are holding KERX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX).

Institutional Ownership by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.